ENO2 and depressive disorder: Given the complex nature of depression and the multifactorial aspects of both ω-3 PUFAs and the biomarkers in question, more targeted studies are necessary to explore how ω-3 PUFA supplementation might affect HMGB1, S100β, and NSE levels in individuals with depression.